Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 June 2023 | Story Department of Communication and Marketing | Photo Charl Devenish
Dr Abraham Matamanda and Prof Lochner Marais
UFS researchers, Dr Abraham R Matamanda, Senior Lecturer in the Department of Geography, and Prof Lochner Marais, Head of the UFS Centre for Development Support, collaborated with researchers in the UK and Brazil on a study on the impact of COVID-19 on children and young people. The study is part of the international PANEX-Youth research project.

Researchers from South Africa, the UK, and Brazil recently conducted a study on the impact of COVID-19 on children and young people, particularly those from disadvantaged households. Their research highlights that the pandemic has deepened existing inequalities, with children and young people’s voices and needs not being considered in policy decisions.

The study conducted by researchers from the University of the Free State (UFS) and the University of Fort Hare in South Africa; the University College London, the University of Birmingham, and Nottingham Trent University in the UK; and the University of São Paulo in Brazil, found that pandemic policy decisions largely ignored young people’s needs, resulting in long-term losses.

Educational inequalities

The report, titled International and National Overviews of the impact of COVID-19 on Education, Food and Play/Leisure and Related Adaptations, outlines how slow government action and policy gaps in efforts to stop the spread of COVID-19 have had a negative impact on children and young people’s health and welfare.

South Africa has been one of the countries hardest hit by COVID-19, and the study shows that due to social isolation and economic disruption caused by lockdowns, children and young people’s education has been stunted, their access to nutritious food has been reduced, and their ability to develop socially through play has been significantly restricted. The impact was worst for those living in disadvantaged poor households.

The study, which is part of the first stage of the PANEX-Youth research project, is divided into two volumes: the ‘Long Report’, highlighting the wider impact of the pandemic on children across the world, while the ‘Short Report’ drills down on the impact on three countries, namely the UK, South Africa, and Brazil.

Further insights from the study show that the digital divide has compounded educational inequalities as education has moved online during the pandemic, with households and regions with insufficient internet access falling behind. Collectively, and combined with the continuing cost-of-living crisis, the researchers believe that these disadvantages are likely to have detrimental consequences for children and young people in the short and long term, with many not yet visible.

Future pandemic planning

The team – which includes UFS researchers, Dr Abraham R Matamanda, Senior Lecturer in the Department of Geography, and Prof Lochner Marais, Head of the UFS Centre for Development Support – expects that policy gaps during the pandemic will negatively impact young people’s professional life trajectories, healthy lifestyles, mental well-being, educational opportunities, and self-confidence.

The team put together five recommendations to ensure that children’s well-being is incorporated into any future pandemic planning. These suggestions include:

  • The need to keep children and young people at the centre of pandemic preparedness efforts.
  • More priority and attention given to the hidden voices and experiences of young people, and particularly those from monetary poor households.
  • Greater recognition that schools play an important, central role as life and care hubs.
  • Greater recognition of play and leisure as rights that are fundamental to children and young people’s development.
  • More structured and systemic responses to multiple dimensions of risk from local and national responses are recommended, based on a rigorous assessment of what worked and failed during the pandemic.

Adapting in the post-pandemic period

Prof Lauren Andres, Professor of Planning and Urban Transformations at the University College London – also the lead author of the report – said: “COVID-19 exposed and exacerbated inequalities that already existed prior to the pandemic. Children and young people’s voices and needs were not heard and accounted for. Our research shows that because of policy gaps and slow government action during the pandemic, disadvantaged children and young people are now facing serious consequences that could be with them for a long time, both here in the UK and around the world.”

According to Dr Matamanda, “The COVID-19 pandemic showed the lack of understanding of what children and young people need in their daily lives. During the pandemic, the rights of children and young people, especially play/leisure, accessing adequate food and education, seemed to be overlooked or least prioritised. This was evident from the slow and inconsistent COVID-19 government policies and strategies that failed to acknowledge the networks and value chains through which children and young people are supported. In this way, our research shows the gaps and inequalities created and widened among children and young people in South Africa, especially those from disadvantaged households who have now been left behind and are grappling to adapt in the post-pandemic period.”

Read the full report here: https://panexyouth.com/

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept